Intra-Cellular Therapies, Inc. (ITCI)

68.80 -1.54 (-2.19%) 收市：04:00PM EDT

Intra-Cellular Therapies, Inc.

430 East 29th Street
New York, NY 10016
United States
646 440 9333
https://www.intracellulartherapies.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 610

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Sharon Mates Ph.D.	Co-Founder, Chairman & CEO	2.34M	2.16M	1953
Mr. Michael I. Halstead J.D.	President	1.03M	2.02M	1973
Dr. Suresh K. Durgam M.D.	Executive VP & Chief Medical Officer	1.01M	無	1969
Mr. Mark Neumann	EVP & Chief Commercial Officer	1.04M	3.08M	1963
Dr. Robert E. Davis Ph.D.	Senior VP & Chief Scientific Officer	646.12k	無	1951
Mr. Juan Fernando Sanchez	Vice President of Corporate Communications & Investor Relations	296.75k	無	1971
Ms. Karen Patruno Sheehy Esq.	Senior VP & Chief Compliance Officer	無	無	1962
John P. Condon	Senior Vice President, General Counsel & Secretary	無	無	無
Dr. Michael Olchaskey	Senior VP & Head of Regulatory Affairs	無	無	無
Mr. John A. Bardi	Senior VP of Market Access, Policy & Government Affairs	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

公司管治

截至 2024年5月1日 止，Intra-Cellular Therapies, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：8；董事會：8；股東權利：7；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。